The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global inhaled nitric oxide market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS. Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region and application.
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.
|Base Year of the Analysis||2020|
|Segment Coverage||Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at